VEGF inhibitors

Ariel Lopez Chavez, Alan Sandler

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Angiogenesis is a fundamental step in the development and progression of malignant tumors. Blockade of angiogenesis in preclinical models prevents the growth of tumor cells and therefore tumor progression. The VEGF pathway is considered to be the major regulator of angiogenesis in normal and malignant tissues. Bevacizumab is the only angiogenesis inhibitor currently approved for use in advanced nonsmall-cell lung cancer. A paclitaxel-based regimen in combination with bevacizumab is the only regimen that has demonstrated a survival advantage in comparison to standard chemotherapy in a Phase III trial. There is a lack of reliable prognostic or predictive biomarkers for selecting patients with nonsmall-cell lung cancer who would benefit from antiangiogenic therapy.

Original languageEnglish (US)
Title of host publicationTargeted Therapies for Non-Small-Cell Lung Cancer
PublisherFuture Medicine Ltd.
Pages35-45
Number of pages11
ISBN (Print)9781780840468, 9781780841236
DOIs
StatePublished - Oct 1 2012
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Non-Small Cell Lung Carcinoma
Neoplasms
Angiogenesis Inhibitors
Paclitaxel
Biomarkers
Drug Therapy
Survival
Growth
Bevacizumab
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chavez, A. L., & Sandler, A. (2012). VEGF inhibitors. In Targeted Therapies for Non-Small-Cell Lung Cancer (pp. 35-45). Future Medicine Ltd.. https://doi.org/10.2217/EBO.12.8

VEGF inhibitors. / Chavez, Ariel Lopez; Sandler, Alan.

Targeted Therapies for Non-Small-Cell Lung Cancer. Future Medicine Ltd., 2012. p. 35-45.

Research output: Chapter in Book/Report/Conference proceedingChapter

Chavez, AL & Sandler, A 2012, VEGF inhibitors. in Targeted Therapies for Non-Small-Cell Lung Cancer. Future Medicine Ltd., pp. 35-45. https://doi.org/10.2217/EBO.12.8
Chavez AL, Sandler A. VEGF inhibitors. In Targeted Therapies for Non-Small-Cell Lung Cancer. Future Medicine Ltd. 2012. p. 35-45 https://doi.org/10.2217/EBO.12.8
Chavez, Ariel Lopez ; Sandler, Alan. / VEGF inhibitors. Targeted Therapies for Non-Small-Cell Lung Cancer. Future Medicine Ltd., 2012. pp. 35-45
@inbook{f4574d8ab9554d31986130fd6db1486c,
title = "VEGF inhibitors",
abstract = "Angiogenesis is a fundamental step in the development and progression of malignant tumors. Blockade of angiogenesis in preclinical models prevents the growth of tumor cells and therefore tumor progression. The VEGF pathway is considered to be the major regulator of angiogenesis in normal and malignant tissues. Bevacizumab is the only angiogenesis inhibitor currently approved for use in advanced nonsmall-cell lung cancer. A paclitaxel-based regimen in combination with bevacizumab is the only regimen that has demonstrated a survival advantage in comparison to standard chemotherapy in a Phase III trial. There is a lack of reliable prognostic or predictive biomarkers for selecting patients with nonsmall-cell lung cancer who would benefit from antiangiogenic therapy.",
author = "Chavez, {Ariel Lopez} and Alan Sandler",
year = "2012",
month = "10",
day = "1",
doi = "10.2217/EBO.12.8",
language = "English (US)",
isbn = "9781780840468",
pages = "35--45",
booktitle = "Targeted Therapies for Non-Small-Cell Lung Cancer",
publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - VEGF inhibitors

AU - Chavez, Ariel Lopez

AU - Sandler, Alan

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Angiogenesis is a fundamental step in the development and progression of malignant tumors. Blockade of angiogenesis in preclinical models prevents the growth of tumor cells and therefore tumor progression. The VEGF pathway is considered to be the major regulator of angiogenesis in normal and malignant tissues. Bevacizumab is the only angiogenesis inhibitor currently approved for use in advanced nonsmall-cell lung cancer. A paclitaxel-based regimen in combination with bevacizumab is the only regimen that has demonstrated a survival advantage in comparison to standard chemotherapy in a Phase III trial. There is a lack of reliable prognostic or predictive biomarkers for selecting patients with nonsmall-cell lung cancer who would benefit from antiangiogenic therapy.

AB - Angiogenesis is a fundamental step in the development and progression of malignant tumors. Blockade of angiogenesis in preclinical models prevents the growth of tumor cells and therefore tumor progression. The VEGF pathway is considered to be the major regulator of angiogenesis in normal and malignant tissues. Bevacizumab is the only angiogenesis inhibitor currently approved for use in advanced nonsmall-cell lung cancer. A paclitaxel-based regimen in combination with bevacizumab is the only regimen that has demonstrated a survival advantage in comparison to standard chemotherapy in a Phase III trial. There is a lack of reliable prognostic or predictive biomarkers for selecting patients with nonsmall-cell lung cancer who would benefit from antiangiogenic therapy.

UR - http://www.scopus.com/inward/record.url?scp=84957403725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957403725&partnerID=8YFLogxK

U2 - 10.2217/EBO.12.8

DO - 10.2217/EBO.12.8

M3 - Chapter

SN - 9781780840468

SN - 9781780841236

SP - 35

EP - 45

BT - Targeted Therapies for Non-Small-Cell Lung Cancer

PB - Future Medicine Ltd.

ER -